AXCELIS TECHNOLOGIES INC ACLS revenue by segment, product and geography
In its fiscal year ending 2025-12-31, AXCELIS TECHNOLOGIES INC reported revenue across 4 products and services; the largest, Ion Implantation Systems Services And Royalties, was $824M (-17.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Ion Implantation Systems Services And Royalties$824Mshare n/a-17.7% yoy
- Product$792Mshare n/a-18.9% yoy
- Services$47Mshare n/a+14.7% yoy
- Other Products Systems Services And Royalties$14.9Mshare n/a-11.1% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$483M57.5%-23.6% yoy
- Asia Pacific$306M36.5%-11.9% yoy
- Europe$50M6.0%+31.2% yoy
Members sum to the consolidated $839M for this period.
- Product$188M94.5%+2.8% yoy
- Services$10.9M5.5%+12.4% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.